Pelthos director granted 19,108 RSUs in Form 4/A
Baxter Richard B reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Baxter Richard B reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. director Richard B. Baxter reported an amended Form 4 reflecting a grant of 19,108 shares of Common Stock, issued at $0.00 per share upon settlement of previously granted restricted stock units (RSUs).
The RSUs were granted as compensation for his service on the board under the company’s 2023 Equity Incentive Plan. They vest in equal quarterly installments over three years, contingent on his continued service, and are settled solely in shares of Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 19,108 shares
Grant/Award
1 txn
Insider
Baxter Richard B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 19,108 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 19,108 shares (Direct)
Footnotes (2)
- F1. Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.
- F2. The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
Key Figures
RSU-related shares: 19,108 shares
Reported share price: $0.00 per share
Post-transaction holdings: 19,108 shares
+1 more
4 metrics
RSU-related shares
19,108 shares
Common Stock issuable upon RSU settlement for board compensation
Reported share price
$0.00 per share
Grant/award acquisition entry on Form 4/A
Post-transaction holdings
19,108 shares
Total common shares reported following this RSU-related grant
Vesting period
3 years
RSUs vest in equal quarterly installments over three years
Key Terms
restricted stock units, 2023 Equity Incentive Plan, Form 4 amendment, vest in equal installments
4 terms
restricted stock units financial
"issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Equity Incentive Plan financial
"RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time"
Form 4 amendment regulatory
"This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4"
vest in equal installments financial
"The RSUs vest in equal installments on a quarterly basis after the date of such grant"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Pelthos Therapeutics (PTHS) report on this Form 4/A?
The filing reports an amended grant of 19,108 shares of Pelthos Therapeutics common stock. These shares are issuable upon settlement of restricted stock units originally disclosed in a prior Form 4, now reclassified from Table II to Table I.
Who received the equity grant disclosed by Pelthos Therapeutics (PTHS)?
Director Richard B. Baxter received the equity grant. The 19,108 restricted stock units were awarded as compensation for his service on the Pelthos Therapeutics board of directors under the company’s 2023 Equity Incentive Plan.
What is the vesting schedule for the Pelthos Therapeutics (PTHS) RSUs?
The RSUs vest in equal quarterly installments over three years after the grant date. Vesting requires that Richard B. Baxter remain in service as a member of Pelthos Therapeutics’ board of directors on each applicable vesting date.
Why is this Pelthos Therapeutics (PTHS) filing labeled as a Form 4 amendment?
It amends an earlier Form 4 that reported the RSUs in the derivative securities table. This amendment moves the same RSU grant into the non-derivative table, clarifying that each unit represents one share of common stock issuable upon settlement.
What plan governs the Pelthos Therapeutics (PTHS) RSU grant to Richard Baxter?
The RSU grant was made under Pelthos Therapeutics’ 2023 Equity Incentive Plan. The plan, as amended from time to time, provides for equity compensation, with these RSUs settling solely in shares of common stock upon vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
